Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;6(6):570-581.
doi: 10.21037/cdt.2016.11.17.

Use of novel oral anticoagulant agents in venous thromboembolism

Shivanshu Madan  1 , Shenil Shah  2 , Patrick Dale  3 , Sasan Partovi  4 , Sahil A Parikh  5
Affiliations
Review

Use of novel oral anticoagulant agents in venous thromboembolism

Shivanshu Madan et al. Cardiovasc Diagn Ther. 2016 Dec.

Abstract

New oral anticoagulants (NOAC) serve as alternatives for patients currently using warfarin for the prevention and treatment of venous thromboembolic (VTE) disease. This article provides a brief summary of the clinical use of these drugs as well as a review of the landmark clinical trials which evaluated described their safety and efficacy. As more data becomes available, a fundamental understanding of these medications will be vital to cardiovascular practitioners managing patients with VTE.

Keywords: Warfarin; apixaban; dabigatran; deep vein; edoxaban; pulmonary embolism (PE); rivaroxaban; thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Site of action of novel oral anticoagulants. Coagulation factors are noted in orange squares. Oral anticoagulants are displayed in red boxes. Rivaroxaban, apixaban and edoxaban are direct factor Xa inhibitors. Dabigatran is a direct thrombin inhibitor.
See this image and copyright information in PMC

References

    1. Luo H, Li J. The specialty of pulmonary vascular medicine in China: historical development and future directions. Cardiovasc Diagn Ther 2012;2:240-5. - PMC - PubMed
    1. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I4-8. 10.1161/01.CIR.0000078468.11849.66 - DOI - PubMed
    1. Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 2014;124:1020-8. 10.1182/blood-2014-03-563056 - DOI - PMC - PubMed
    1. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106. 10.1001/archinte.165.10.1095 - DOI - PubMed
    1. Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992;32:196-209. 10.1002/j.1552-4604.1992.tb03827.x - DOI - PubMed